Clopidogrel suspension, without rebound in stable patients

Original title: A randomised controlled trial of platelet activity before and after cessation of clopidogrel therapy in patients with stable cardiovascular disease. Reference: Ford I et al. J Am Coll Cardiol. 2013;E-pub ahead of print.

Some previous studies have suggested an excess of cardiovascular events after discontinuation of clopidogrel, and this could be due to a rebound effect on platelet activity caused by drug discontinuation. Still, none of this works performed a measuring of the baseline platelet activity, so rebound theory was never confirmed.

This study randomized 171 patients with stable coronary or peripheral disease who were receiving aspirin to clopidogrel or placebo for 30 days. Blood samples were taken at the time of starting treatment, immediately before of holdup and at 7, 14 and 28 days after the suspension. The baseline characteristics of both groups were well balanced. The platelet reactivity measured by platelet adhesion to fibrinogen stimulated by ADP decreased in the clopidogrel group during treatment and then gradually returned to baseline with the suspension. Platelet reactivity was unchanged in the placebo group. The mean reactivity measured in the clopidogrel group was 73.9 % at baseline and 30.9 % of the length of the treatment. After suspension, it was increasing gradually , resulting 69.2 % after 7 days , 75.6 % at 14 days and 77.3% at 28 days (p <0.0001 for all differences). Other secondary measurements were also conducted, including the expression of P- selective ADP induced platelet, in which we observed the same progressive pattern with the exception of the binding to non-stimulated fibrinogen. 

Conclusion:

This study found no evidence of a rebound effect of platelet activity above baseline after discontinuation of clopidogrel in patients with ischemic heart disease or stable peripheral vascular disease.

Editorial Comment

While the rebound effect in laboratory measurements seems to be discarded, from the clinical point of view, it could cause events due to the loss of drug protection rather than exaggerated platelet activity. 

SOLACI.ORG

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...